Breast cancer (BC) screening enables early detection and timely treatment of cancer.
Improving the effectiveness of BC screening can be accomplished by personalizing …

Breast cancer is the most diagnosed cancer among women worldwide, with an estimated
2.3 million new cases and 670,000 deaths reported in 2022 (1). Advances in genomic …

Background Most breast biopsies are diagnosed as benign breast disease, with 1.5-to 4-fold
increased breast cancer risk. Apart from pathologic diagnoses of atypical hyperplasia, few …

Background The polygenic risk score (PRS) allows the quantification of the polygenic effect
of many low‐penetrance alleles on the risk of breast cancer (BC). This study aimed to …

Background Breast cancer has been the most frequently diagnosed cancer among women
in Taiwan since 2003. While genetic variants play a significant role in the elevated risk of …

Breast cancer (BC) is the most prominent tumor type among women, accounting for 32% of
newly diagnosed cancer cases. BC risk factors include inherited germline pathogenic gene …

Breast cancer (BC) remains the most common malignant tumor site and the leading cause of
cancer-related deaths in women despite the wide availability of screening programs and …

Background/Objectives: Polygenic risk scores (PRSs) have been extensively studied and
are increasingly applied in healthcare. One of the most studied and developed areas is …

Biomedical research and its applications in healthcare are undergoing exponential growth,
fueled by a global commitment to improve human health through advanced genomics and …

Background: The polygenic risk score (PRS) allows the quantification of the polygenic effect
of many low‐penetrance alleles on the risk of breast cancer (BC). This study aimed to …